Lijun Mao

Dr. Lijun Mao


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2024 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
KZKaichen Zhou
Kaichen Zhou
HLHaosen Lu
Haosen Lu
JZJielin Zhang
Jielin Zhang
QSQi Shen
Qi Shen
PLPengzhan Liu
Pengzhan Liu
LMLijun Mao
Lijun Mao
Prostate cancer is the most common malignant tumor in male genitourinary system. The incidence of prostate cancer ranks the first among all male malignant tumors worldwide, and the mortality rate ranks the second among all male malignant tumors. Prostate stem cells are heterogeneous subsets with the function of self-regeneration and proliferation in the prostate, which can produce all cell lineages that make up the prostate epithelium. At present, the pathogenesis of prostate cancer remains unclear. According to cancer stem cell hypothesis, prostate cancer may be a stem cell disease, which provides a new direction for revealing the pathogenesis of prostate cancer and developing treatment strategy for prostate cancer. In this mini-review, we highlight recent advances in our understanding of the origin, surface molecular markers, signaling pathway and the significance for clinical treatment of prostate cancer stem cells.

1 January 2023 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
JWJie Wang
Jie Wang
KZKaichen Zhou
Kaichen Zhou
HZHuihuang Zhu
Huihuang Zhu
FWFukun Wei
Fukun Wei
SMSai Ma
Sai Ma
LMLijun Mao
Lijun Mao
At present, common treatments of prostate cancer mainly include surgery, radiotherapy, chemotherapy and hormone therapy. However, patients have high recurrence rate after treatment, and are prone to castration-resistant prostate cancer. Tumor vaccine is based on tumor specific antigen (TSA) and tumor associated antigen (TAA) to activate specific immune response of the body to cancer cells. With continuous maturity of tumor vaccine technology, different forms of prostate cancer vaccines have been developed, such as cellular vaccines, extracellular-based anti-tumor vaccines, polypeptide vaccines, and nucleic acid vaccines. In this review, we summarize current status and progress in the development of prostate cancer vaccines.

22 December 2024 in Discover Oncology
Verified
Journal Article
Open access
QSQi Shen
Qi Shen
KZKaichen Zhou
Kaichen Zhou
HLHaosen Lu
Haosen Lu
JZJielin Zhang
Jielin Zhang
QXQiqing Xu
Qiqing Xu
LMLijun Mao
Lijun Mao
High expression of immune checkpoint molecule B7-H3 (CD276) in many cancer types makes it a promising immunotherapeutic target. Both coinhibitory and costimulatory effects of B7-H3 in tumors have been demonstrated, but the mechanism of B7-H3 immune response under dual effects is open to question. B7-H3 is crucially involved in the migration and invasion, angiogenesis, metabolism and chemotherapy resistance of prostate cancer. In addition to the potential immune effects on tumor environment, B7-H3 plays a non-immune-mediated role in tumor progression. In this review, we summarize current understanding of molecular mechanism of B7-H3 in prostate cancer and discuss the potential of B7-H3 as a novel therapeutic target for prostate cancer.

1 January 2021 in Journal of Cancer
Verified
Journal Article
Open access
LMLijun Mao
Lijun Mao
HYHaiyuan Yu
Haiyuan Yu
SMSai Ma
Sai Ma
ZXZiyang Xu
Ziyang Xu
FWFukun Wei
Fukun Wei
JZJunnian Zheng
Junnian Zheng
Background: Oncolytic viral therapy is a new strategy for tumor eradication which combines the advantages of viral therapy and gene therapy. Silencing SATB1 exhibits strong inhibitory effect on the growth of prostate cancer. Docetaxel (DTX) is the gold standard for chemotherapy of prostate cancer, but its side effects decrease the life quality of patients. Therefore, it is urgent to develop combination therapy to increase its anti-tumor effect.

1 November 2021
Verified
Journal Article
Closed access
MLMeng Lu
Meng Lu
FWFukun Wei
Fukun Wei
SMSai Ma
Sai Ma
ZXZiyang Xu
Ziyang Xu
JWJie Wang
Jie Wang
LMLijun Mao
Lijun Mao

1 July 2021
Verified
Journal Article
Closed access
YKYi Kan
Yi Kan
BLBingheng Li
Bingheng Li
DYDongliang Yang
Dongliang Yang
YLYirui Liu
Yirui Liu
JLJihai Liu
Jihai Liu
LMLijun Mao
Lijun Mao